F5
F5 encodes Factor V, a central accelerator of the blood clotting cascade. The Factor V Leiden variant is the most common genetic cause of inherited thrombophilia, leading to a state of "APC resistance" and significantly increased risk of blood clots.
Key Takeaways
- •Factor V is an essential co-factor that speeds up the production of thrombin.
- •The Factor V Leiden variant (rs6025) makes the protein resistant to being "turned off."
- •Carriers of FVL have a 3-8x higher risk of venous thromboembolism (VTE).
- •Risk is exponentially increased when FVL is combined with oral contraceptives or long-haul travel.
Basic Information
- Gene Symbol
- F5
- Full Name
- Coagulation Factor V
- Also Known As
- F5RFactor V
- Location
- 1q24.2
- Protein Type
- Coagulation Factor
- Protein Family
- Multicopper oxidase family
Related Isoforms
Key SNPs
The Factor V Leiden variant. Eliminates one of the APC cleavage sites, leading to APC resistance and a significant lifelong increase in thrombotic risk.
Common variant associated with variations in plasma Factor V levels and potentially modulating the risk of pregnancy complications.
Known as the "R2 haplotype"; associated with slightly reduced Factor V levels and a mild increase in the risk of thrombosis when co-inherited with Factor V Leiden.
Overview
F5 encodes Coagulation Factor V (Factor Five), a large glycoprotein that circulates in the blood in an inactive form. When a blood vessel is injured, Factor V is activated by thrombin. Once active, it serves as a critical co-factor for the "prothrombinase complex," which acts like a biological engine to convert prothrombin into active thrombin—the final enzyme that builds a blood clot.
The balance of clotting is maintained by a natural off-switch called Activated Protein C (APC). Normally, APC cuts and inactivates Factor V once the clot is formed. The Factor V Leiden (FVL) mutation changes the protein just enough that APC can no longer "cut" it efficiently. This leads to a state of Activated Protein C Resistance, where the clotting engine stays running longer than it should, predisposing the individual to deep vein thrombosis (DVT) and pulmonary embolism.
Conceptual Model
A simplified mental model for the pathway:
Factor V Leiden is an "accelerator" that cannot be easily disengaged.
Core Health Impacts
- • Clot Formation: Essential for the rapid generation of thrombin to seal vascular leaks
- • Thrombotic Risk: Primary genetic modifier of the risk for Deep Vein Thrombosis (DVT)
- • Pregnancy Health: Variants are linked to an increased risk of recurrent pregnancy loss and preeclampsia
- • Wound Healing: Initiates the fibrin-building phase required for permanent tissue repair
- • Inflammation Link: Thrombin generated via Factor V acts as a pro-inflammatory signaling molecule
Protein Domains
A-Domains
Structural domains (A1, A2, A3) that provide the framework for interaction with Factor Xa and membranes.
C-Domains
C-terminal domains (C1, C2) that bind to the negatively charged phospholipids on the surface of activated platelets.
B-Domain
The large inhibitory domain that is cleaved away by thrombin to activate the protein.
Upstream Regulators
Thrombin (Factor IIa) Activator
The primary activator; cleaves the B-domain of Factor V to "turn on" its co-factor activity.
Factor Xa Activator
The enzymatic partner; binds Factor V on the platelet surface to form the prothrombinase complex.
Activated Protein C (APC) Inhibitor
The primary natural inhibitor; cleaves Factor Va at specific sites (including Arg506) to stop clotting.
Calcium (Ca²⁺) Activator
Essential divalent cation required for the structural stability and membrane binding of Factor V.
Estrogen Modulator
Increases the levels of Factor V and other clotting factors while decreasing the activity of the APC system.
Downstream Targets
Thrombin Generation Activates
Factor V increases the rate of thrombin production by Factor Xa by over 1,000-fold.
Prothrombinase Complex Activates
The multi-protein machine (Xa, Va, Ca, Phospholipid) that is the definitive engine of clotting.
Fibrin Formation Activates
The final clot material, whose production depends on the thrombin generated via Factor V.
Clot Stability Activates
Factor V activity determines the density and resilience of the resulting fibrin mesh.
Venous Thromboembolism Activates
The clinical output of over-active Factor V; includes DVT and pulmonary embolism.
Role in Aging
Factor V function is a critical component of "vascular resilience." As we age, the clotting system naturally tips toward a pro-thrombotic state (hypercoagulability), making the genetic status of F5 a major modifier of cardiovascular health in the elderly.
Hypercoagulable Shift
Aging involves a steady increase in clotting factor levels and a decline in natural anticoagulants like Protein C.
VTE Latency
Factor V Leiden carriers often remain "clot-free" for decades until age-related factors (immobility, surgery) trip the threshold.
Post-Thrombotic Syndrome
Older individuals are more prone to the chronic leg pain and swelling that results from F5-mediated clots.
Inflammaging Crosstalk
Chronic low-grade inflammation upregulates the clotting cascade, exacerbating the risks associated with F5 variants.
Vascular Dementia
Micro-clots in the brain, influenced by systemic clotting tone, are a known contributor to age-related cognitive decline.
Longevity Selection
Populations with very high longevity often show a lower-than-average frequency of pro-thrombotic F5 variants.
Disorders & Diseases
Factor V Leiden (FVL)
The most common inherited risk factor for DVT. Occurs in 3-5% of Caucasians. Heterozygotes have a 3-8x increased risk; homozygotes have up to an 80x risk.
Deep Vein Thrombosis (DVT)
Blood clots in the large veins of the legs, frequently driven by F5 mutations and triggered by immobility.
Pulmonary Embolism (PE)
The most serious complication of F5 mutations, where a leg clot breaks loose and travels to the lungs.
Factor V Deficiency
A rare bleeding disorder (Owren’s disease) caused by lack of F5, characterized by easy bruising and mucosal bleeding.
Recurrent Pregnancy Loss
F5 mutations can cause micro-clots in the placenta, leading to fetal loss and other obstetric complications.
The Oral Contraceptive Synergy
Women with Factor V Leiden who take estrogen-containing birth control have a 30-fold increased risk of blood clots compared to non-carriers not on the pill.
Interventions
Supplements
Reported to have mild anti-platelet effects that may support overall vascular fluidity.
An enzyme from fermented soy studied for its ability to support fibrinolytic (clot-dissolving) activity.
May have modest anticoagulant properties by inhibiting the vitamin K-dependent clotting cycle.
Contains gingerols reported to interfere with certain steps of the coagulation cascade in experimental models.
Lifestyle
Critical for F5 carriers; ankle pumps and walking during long-haul travel prevent the venous stasis that triggers clots.
Adequate water intake maintains blood viscosity and prevents the hemoconcentration that favors clotting.
Mechanical support to improve venous return in the legs, reducing the physical trigger for thrombosis.
Reduces the systemic cytokine load that otherwise primes the liver to produce more clotting factors.
Medicines
Fast-acting anticoagulants that catalyze antithrombin to shut down the cascade accelerated by Factor V.
Vitamin K antagonist that reduces the production of several factors that work in tandem with Factor V.
Direct Oral Anticoagulants that block Factor Xa, the enzyme that requires Factor V as a co-factor.
Primarily an anti-platelet agent; while not a direct F5 blocker, it reduces the surface area available for F5 activity.
Lab Tests & Biomarkers
Genetic Screening
The definitive DNA test for the rs6025 mutation. Standard for patients with unexplained clots.
Combines F5, F2 (Prothrombin), and MTHFR to assess total inherited clotting risk.
Functional Assays
A functional test that measures how well a patient's blood responds to the APC "off-switch."
A measure of the "extrinsic" pathway of clotting, which is dependent on Factor V levels.
Clot Monitoring
A blood marker of active clot breakdown; used to rule out DVT or PE in emergency settings.
Measures the concentration of functional Factor V protein in the plasma.
Hormonal Interactions
Estrogen Primary Risk Factor
Drives the liver to produce more Factor V and suppresses the Protein C system, exponentially increasing FVL risk.
Progesterone Modulator
Generally considered safer than estrogen for F5 carriers, but high doses may still influence clotting tone.
Cortisol Upregulator
Chronic stress can increase the production of clotting factors as part of the body's preparedness for injury.
Erythropoietin Indirect Regulator
Increases red cell mass, which impacts blood viscosity and the flow dynamics that interact with the F5 system.
Deep Dive
Network Diagrams
Factor V: The Clotting Turbo
The Clotting Turbo: Factor V and Thrombin
To understand F5, one must view the blood clotting cascade as a precision-engineered machine. When you are cut, your body needs to turn liquid blood into a solid gel (fibrin) instantly.
The Accelerator: Factor V is the primary accelerator of this process. On its own, the enzyme Factor Xa can turn prothrombin into thrombin, but it is extremely slow—too slow to stop a bleed. When Factor V is activated, it binds to Factor Xa on the surface of platelets, creating the prothrombinase complex. This complex is 1,000 times more powerful than the enzyme alone, allowing for the “thrombin burst” required for life.
The B-Domain: Factor V is born with a massive “B-domain” that acts like a safety pin, keeping the protein inactive. During an injury, the first few drops of thrombin cut this pin away, “unleashing” the Factor V turbo to finish the job.
Factor V Leiden: The “Uncuttable” Protein
The most common genetic cause of blood clots is Factor V Leiden (rs6025).
The APC Switch: Under normal conditions, once a clot is formed, the body sends in a protein called Activated Protein C (APC). APC acts like a pair of molecular scissors. It finds a specific spot on Factor V (position 506) and cuts it, turning the turbo off.
Resistance to Control: The Leiden mutation changes that specific spot from Arginine to Glutamine. The APC “scissors” can no longer find the cutting site. As a result, the Factor V turbo stays active for longer than necessary. This leads to APC Resistance, where the blood remains in a “ready-to-clot” state far beyond what is required for safety.
The Synergistic Trap: F5 and Estrogen
A vital clinical lesson of F5 involves its interaction with the hormone estrogen.
The Double Hit: Estrogen (from birth control or HRT) naturally increases the production of Factor V while simultaneously making the APC “scissors” less effective.
Exponential Risk: For a woman with the Factor V Leiden mutation, taking oral contraceptives creates a “double hit” on the same pathway. Her genetic “turbo” is already hard to turn off, and the hormones add even more turbo fuel while further dulling the brakes. This synergy increases the risk of a life-threatening blood clot by 30-fold, representing one of the most significant gene-environment interactions in female health.
Practical Note: The Traveler’s Risk
Immobility is the trigger. Factor V Leiden is a "susceptibility," but it usually requires a trigger. Long flights (over 4 hours) are the most common physical trigger because the lack of calf muscle pumping allows blood to pool, giving the over-active F5 system time to build a clot.
Hormonal Caution. Any woman with a family history of blood clots must be screened for F5 variants before starting estrogen-based birth control or hormone replacement therapy, as the risk multiplier is among the highest in clinical medicine.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The landmark study that first identified the Factor V Leiden mutation and its link to inherited thrombophilia.
Comprehensive review detailing the molecular mechanism of APC resistance and the evolution of the FVL allele.
The first major epidemiological study to prove the deadly synergy between F5 mutations and hormonal birth control.
Detailed the biochemistry of how Factor V serves as the essential catalytic scaffold for thrombin production.
Characterized the age-related shifts in the F5 system that increase the risk of thrombosis in later life.